Cybin Inc (HELP)

Cybin Inc., which does business as Helus Pharma, is a clinical-stage neuropsychiatry company focused on developing psychedelic-based therapeutics for people with mental health conditions. The company’s pipeline includes CYB003, a deuterated psilocybin analog being evaluated in a phase 3 trial for major depressive disorder, and CYB004, a deuterated N, N-dimethyltryptamine (DMT) program in phase 2 testing for generalized anxiety disorders. Its additional programs include SPL028, an injectable deuterated DMT that has completed phase 1 intramuscular and intravenous clinical studies, SPL026 for major depressive disorder, and CYB005, a phenethylamine derivative in preclinical development for central nervous system disorders. Cybin also maintains a broader research pipeline of investigational psychedelic-based compounds and has a strategic partnership with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program for CYB003 in adjunctive major depressive disorder. The company is headquartered in Toronto, Canada.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.